Downloaded 10 times
Uploaded byKisaco Research
Robin Low, CEO & Founder, Areton Pte Ltd
Areteon Pte Ltd is a company that develops veterinary therapeutics and has patented a novel antimicrobial and antifungal drug called DMDC. DMDC has a unique mode of action in that it electrostatically binds to negatively charged bacterial cells and causes lysis without needing to penetrate the cells, meaning bacteria cannot develop resistance. Clinical trials showed DMDC was effective in reducing bacterial loads and symptoms in dogs with skin infections when formulated in a 4% shampoo. Toxicity studies found DMDC to have an oral LD50 over 2000 mg/kg in rats. The company has received over $1.3 million in funding and aims to launch new topical products containing DMDC
More Related Content
Similar to Robin Low, CEO & Founder, Areton Pte Ltd
Robin Low, CEO & Founder, Areton Pte Ltd
- 1. ARETEON PTE LTD 亚绿基公司 Wecreate possibilities in veterinary therapeutics INVESTMENT/BUSINESS OPPORTUNITY PATENTED, NON- BACTERIAL RESISTANCE ANTIMICROBIAL AND ANTI-FUNGAL DRUG
- 2. ©AreteonPteLtd 2ANTIMICROBIAL DRUG RESISTANCE 1.The first anti-microbial drug was discovered in 1929 : Penicillin 2. The last true antibiotic was discovered in 1960s 3. Today, there are only 7 antibiotic scaffolds. All the so-called recent “discoveries” are based on manipulating the existing scaffolds. This encourages multi-drug resistance very rapidly
- 3. ©AreteonPteLtd 3ANTIMICROBIAL DRUG RESISTANCE Antimicrobialdrugs need to enter the bacterium to be able to kill the bacterium or stop it from replicating Mode of action #1
- 4. ©AreteonPteLtd 4ANTIMICROBIAL DRUG RESISTANCE Modeof action #2 Antimicrobial drugs need to breakthrough the biofilm that protects the bacteria
- 5. ©AreteonPteLtd 5DMDC: NOVEL MODEOF ACTION Patent pending; PCT/SG2014/000053 Poly-cationic chitosan-based polymer Quaternary ammonium (positively charged) Glucosamine moiety PEG
- 6. ©AreteonPteLtd 6DMDC: NOVEL MODEOF ACTION Patent pending; PCT/SG2014/000053 RNA DNA Cell wall (negatively charged) Staphylococcus aureus DMDC (positively charged) Electrostatic bonding
- 7. ©AreteonPteLtd 7DMDC: NOVEL MODEOF ACTION Patent pending; PCT/SG2014/000053 Staphylococcus aureus DMDC (positively charged) Bacterial lysis = bactericidal
- 8. ©AreteonPteLtd 8DMDC: NOVEL MODEOF ACTION Patent pending; PCT/SG2014/000053 Does not need to penetrate the bacterium Cannot be neutralized by the enzymes in the bacterium No risk of bacterial resistance to DMDC
- 9. ©AreteonPteLtd 9DMDC: NOVEL MODEOF ACTION Patent pending; PCT/SG2014/000053 Treatment by DMDC Electron-microscopy of destruction of S. aureus Perforation of cell wall = Death of bacteria
- 10. ©AreteonPteLtd 10DMDC: TRIALS CONDUCTED Patentpending; PCT/SG2014/000053 Efficacy: 4% shampoo formulation Observation parameters Treatment period Day 0 Day 7 Day 14 Day 21 Pruritus1 Owner Clinician 4.33 4.00 3.33 3.33 3.00 2.67 2.33 2.33 Bacterial Load2 Papules Pustules Skin flakes 2.28 2.56 2.00 1.67 2.11 1.50 1.44 1.72 1.00 0.56 0.94 0.00 Symptoms 3 Papules Pustules Skin flakes Scabs/Dandruff 3.67 3.00 2.50 3.50 3.67 2.67 2.50 2.50 3.00 2.33 1.50 2.50 2.33 2.33 1.50 2.00 Fur Coat4 Shine Odour Fur loss 4.00 3.67 4.00 3.67 2.67 4.00 3.00 2.33 4.00 2.33 1.67 3.00
- 11. ©AreteonPteLtd 11DMDC: 3X MinimumInhibitory Concentration Trials Conducted for “OralGarde” Veterinary Mouth-Spray Patent pending; PCT/SG2014/000053 S. aureus (μg/mL) E. coli (μg/mL) P. aeruginosa (μg/mL) MRSA (μg/mL) 12.5 25 25 15 12.5 25 25 15 12.5 25 25 15
- 12. ©AreteonPteLtd 12DMDC: TRIALS CONDUCTED Patentpending; PCT/SG2014/000053 Safety: Acute oral toxicity (OECD guideline 423) 1. LD50 > 2,000 mg/kg of body weight. 2. All rats appeared normal thereafter till euthanized. No untoward clinical signs were observed during this period. 3. All rats did not have significant lesions observed on gross pathology.
- 13. ©AreteonPteLtd 13DMDC: MILESTONES ACHIEVED Patentpending; PCT/SG2014/000053 S$600,000 seed funding by business angel in May 2012 Successful completion of preliminary trials on potency, efficacy and safety on Sep 2013 Optimization of chemical synthesis at mass - production scale with significantly improved potency. Sales launch in Q1 2017 new Topical Products formulated with DMDC significantly improved potency and raise capital for expansion. S$725,000 Singapore government funding between Jan 2013 and Dec 2015
- 14. ©AreteonPteLtd 14 ARETEON PTE LTD 亚绿基公司 Wecreate possibilities in veterinary therapeutics ARETEON PTE LTD 19 Tai Seng Avenue, #06-19 Home-Fix Building, Singapore 534054 THANK YOU !